{"id":8124,"date":"2026-05-04T13:55:19","date_gmt":"2026-05-04T13:55:19","guid":{"rendered":"https:\/\/starnews1.online\/?p=8124"},"modified":"2026-05-04T13:55:19","modified_gmt":"2026-05-04T13:55:19","slug":"these-are-the-signs-that-he-is-cr-see-more-3","status":"publish","type":"post","link":"https:\/\/starnews1.online\/?p=8124","title":{"rendered":"These are the signs that he is cr\u2026 See more"},"content":{"rendered":"

Disclaimer:\u00a0<\/strong>This article is for informational and educational purposes only and does not constitute medical advice. It is based on peer-reviewed literature and reputable medical sources including the National Organization for Rare Disorders (NORD), DermNet NZ, PubMed, and the U.S. National Institutes of Health (NIH). Readers should not make changes to their treatment plan based solely on this information and are encouraged to consult a qualified healthcare professional for personalized medical advice.<\/em><\/p>\n

<\/div>\n
\n
<\/div>\n
<\/div>\n<\/div>\n

In everyday medical practice, clinicians often make small adjustments to a patient\u2019s treatment plan\u2014switching medications, updating dosages, or changing drug delivery methods. Most of the time, these changes improve symptoms and enhance quality of life. But occasionally, a routine decision can uncover something completely unexpected.<\/p>\n

\n
<\/div>\n
<\/div>\n<\/div>\n

This was the case for a 55-year-old woman living with chronic obstructive pulmonary disease (COPD). For years, she had been stable on her medications. Then, following a switch to a new inhaler, she developed a painful and rare skin condition known as\u00a0Sweet syndrome<\/strong>\u2014a reaction so unusual that it may represent the first documented case linked to inhaled therapy.<\/p>\n

<\/div>\n
<\/div>\n

The Patient\u2019s Journey: From Stability to Sudden Symptoms<\/h2>\n

The patient\u2019s medical background included\u00a0hypertension<\/strong>\u00a0and long-term\u00a0COPD management<\/strong>. Her treatment plan featured\u00a0enalapril<\/strong>\u00a0for blood pressure control and a\u00a0formoterol-based inhaler<\/strong>\u00a0for her respiratory condition. For years, she had been doing relatively well.<\/p>\n

\n
<\/div>\n
<\/div>\n<\/div>\n

But as her lung function began to decline, her pulmonologist decided to make an adjustment, prescribing a new combination inhaler containing\u00a0indacaterol and glycopyrronium<\/strong>. This was considered a standard, evidence-based decision, intended to improve her breathing and slow further COPD progression.<\/p>\n

\n
<\/div>\n
<\/div>\n<\/div>\n

Yet, just\u00a048 hours after starting the new inhaler<\/strong>, the patient experienced something completely unexpected:<\/p>\n